Clinical Trial Facilities in the US and China

Clinical Research Center in the US with 88 beds

 

Gallery: Clinical
 Jida-Center-015

With 88 beds, our newly renovated Clinical Research Center is located in Hackensack, NJ, within 15 miles of New York City. The Frontage facility is situated in an ethnically and socioeconomically diverse region, close to a major medical center and within easy traveling distance of major airports and other transportation.  A full time primary investigator oversees the site, and a growing number of part time primary investigators are coming aboard to support our clients' clinical studies.

 

Three Hosptial-based Clinical Research Centers in China with 250 beds

 

Frontage’s China Clinical Research Centers operate under the same standard operating procedures as the Clinical Research Center in the United States. Additionally, the research staff and leadership team in China have all received their training in the United States.

 

Our 130-bed, hospital-based Clinical Research Center is located in Zhengzhou, China, approximately a one-hour flight from Beijing.  The Zhengzhou Clinical Research Center was opened in 2009 and is based in the First Affiliated Hospital of Zhengzhou University, a 6,000-bed facility that is considered one of the top hospitals in China.

Our other clinical centers in China are located at Jilin University, with 80 beds, and Henan TCM University Hospital, also with 80 beds.  

Among the trials we perform in the US and China are:

 

  • First-in-human, single and multiple ascending doses
  • Repeat Dose
  • Proof-of-concept
  • Pharmacodynamic
  • Absolute and Relative Bioavailability
  • Fed-fasted Bioequivalence, Food Effect
  • Drug-drug interaction and Drug-alcohol interaction studies

Experience with Targeted Patient Populations

 

Frontage also has significant experience performing studies in targeted patient populations, such as those for cardiovascular, metabolic, osteoarthritic, urologic and dermatologic disorders, as well as studies involving pre- and post-menopausal women, men and women with obesity and metabolic syndrome and men with low testosterone.